Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(17):1403-1413; doi:10.1093/jnci/92.17.1403
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chen, X.
Right arrow Articles by Keyomarsi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, X.
Right arrow Articles by Keyomarsi, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 17, 1403-1413, September 6, 2000
© 2000 Oxford University Press

Activation of the Estrogen-Signaling Pathway by p21WAF1/CIP1 in Estrogen Receptor-Negative Breast Cancer Cells

Xiaomei Chen, Christopher Danes, Michael Lowe, Thaddeus W. Herliczek, Khandan Keyomarsi

Affiliations of authors: X. Chen, C. Danes, M. Lowe, T. W. Herliczek, Division of Molecular Medicine, Wadsworth Center, Albany, NY; K. Keyomarsi, Division of Molecular Medicine, Wadsworth Center, and Department of Biomedical Sciences, State University of New York, Albany.

Correspondence to and present address: Khandan Keyomarsi, Ph.D., Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 66, Houston, TX 77030-4095 (e-mail: kkeyomar{at}mdanderson.org).

Background: Estrogen stimulates the proliferation of cells in normal mammary glands and most estrogen receptor (ER)-positive mammary carcinomas by binding to the ER and promoting the transcription of ER-responsive genes. In cells with functional ERs, estrogen mediates the transition of cells from the G1 to S phase of the cell cycle. Several cell cycle regulatory proteins have been implicated in the ER-signaling pathway involved in estrogen-mediated growth stimulation and antiestrogen-mediated growth arrest. We sought to determine whether p21, a cyclin-dependent kinase inhibitor, is a component of this pathway and, if so, whether it can mediate estrogen's action in ER-negative breast cancer cells. Methods: We overexpressed p21 with a tetracycline-inducible system in ER-negative, p21-negative breast cancer cells. Activity of the ER-signaling pathway was monitored in transient transfection assays by using constructs in which the ER promoter or the estrogen-response element (ERE) controls Luciferase expression. The growth-modulating effects of estradiol and antiestrogens on p21-overexpressing clones were assessed. All P values are from two-sided tests. Results: A strong positive association was found between the expression of p21 and ER in nine breast cancer cell lines and in tumor samples from 60 patients with breast cancer (P<.001). Overexpression of p21 in a p21-negative, ER-negative cell line induced both the ER and ERE promoters in an estrogen-responsive manner. Last, stable p21 clones that also lack the expression of wild-type ER were responsive to the growth-inhibitory effects of ICI 182,780, a potent antiestrogen, and the growth-stimulatory effects of 17ß-estradiol. Conclusion: The ability of p21 to mediate the activation of the estrogen-signaling pathway in ER-negative tumor cells suggests that p21 plays a novel role in this pathway, a finding that also has important clinical implications.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Vet PatholHome page
E. Radaelli, A. Arnold, A. Papanikolaou, R. A. Garcia-Fernandez, S. Mattiello, E. Scanziani, and R. D. Cardiff
Mammary Tumor Phenotypes in Wild-Type Aging Female FVB/N Mice with Pituitary Prolactinomas
Vet. Pathol., July 1, 2009; 46(4): 736 - 745.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. Pang, J. Dong, and P. Thomas
Estrogen Signaling Characteristics of Atlantic Croaker G Protein-Coupled Receptor 30 (GPR30) and Evidence It Is Involved in Maintenance of Oocyte Meiotic Arrest
Endocrinology, July 1, 2008; 149(7): 3410 - 3426.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
R. I. Fernando and J. Wimalasena
Estradiol Abrogates Apoptosis in Breast Cancer Cells through Inactivation of BAD: Ras-dependent Nongenomic Pathways Requiring Signaling through ERK and Akt
Mol. Biol. Cell, July 1, 2004; 15(7): 3266 - 3284.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M J Pellikainen, T T Pekola, K M Ropponen, V V Kataja, J K Kellokoski, M J Eskelinen, and V-M Kosma
p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis
J. Clin. Pathol., March 1, 2003; 56(3): 214 - 220.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Vanzulli, A. Efeyan, F. Benavides, L. A. Helguero, G. Peters, J. Shen, C. J. Conti, C. Lanari, and A. Molinolo
p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas
Carcinogenesis, May 1, 2002; 23(5): 749 - 758.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.